Effects of long-term administration of enalapril on clinical indicators of renal function in dogs with compensated mitral regurgitation.
OBJECTIVE
To determine the effect of long-term administration of enalapril on renal function in dogs with severe, compensated mitral regurgitation.


METHODS
Randomized controlled trial.


METHODS
139 dogs with mitral regurgitation but without overt signs of heart failure.


METHODS
Dogs were randomly assigned to be treated with enalapril (0.5 mg/kg [0.23 mg/lb], PO, q 24 h) or placebo, and serum creatinine and urea nitrogen concentrations were measured at regular intervals for up to 26 months.


RESULTS
Adequate information on renal function was obtained from 132 dogs; follow-up time ranged from 0.5 to 26 months (median, 12 months). Mean serum creatinine and urea nitrogen concentrations were not significantly different between dogs receiving enalapril and dogs receiving the placebo at any time, nor were concentrations significantly different from baseline concentrations. Proportions of dogs that developed azotemia or that had a +/- 35% increase in serum creatinine or urea nitrogen concentration were also not significantly different between groups.


CONCLUSIONS
And Clinical Relevance: Results suggest that administration of enalapril for up to 2 years did not have any demonstrable adverse effects on renal function in dogs with severe, compensated mitral regurgitation.
Atkins
Clarke E
CE
Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh 27606, USA.
Brown
William A
WA
Coats
Julie R
JR
Crawford
Mary Ann
MA
DeFrancesco
Teresa C
TC
Edwards
Joel
J
Fox
Philip R
PR
Keene
Bruce W
BW
Lehmkuhl
Linda
L
Luethy
Michael
M
Meurs
Kate
K
Petrie
Jean-Paul
JP
Pipers
Frank
F
Rosenthal
Steven
S
Sidley
Jennifer A
JA
Straus
Justin
J
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000818:Animals; D001806:Blood Urea Nitrogen; D003404:Creatinine / Q000097:blood; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004656:Enalapril / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D007668:Kidney / Q000187:drug effects*; D007677:Kidney Function Tests / Q000662:veterinary; D008297:Male; D008944:Mitral Valve Insufficiency / Q000150:complications / Q000188:drug therapy / Q000662:veterinary*; D013997:Time Factors
D000806:Angiotensin-Converting Enzyme Inhibitors; D004656:Enalapril; D003404:Creatinine